Abstract
Objective: Homologous recombination deficiency (HRD), identified by HRD genomic alterations (GA) or percentage gLOH, correlates with PARP inhibitor response in ovarian cancer (OC). Since the copy number high (CN-H) TCGA EC molecular subtype (EC-MS) shares molecular features with high-grade OC, our aim was to evaluate the role of gLOH in predicting PS and as a marker of HRD.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
